Release date: 2017-11-09 Multiple myeloma is a relatively common type of blood cancer, and Osaka University of Japan has recently developed a new type of immunotherapy for the treatment of this disease. According to reports, there are about 18,000 patients with multiple myeloma in Japan. Although the treatment level has been significantly improved and the survival of patients has been prolonged, it is extremely difficult to completely cure and is prone to recurrence. A research team at Osaka University found that a protein called integrin β7 was found only on the surface of myeloma cells and was not found on normal cells. The researchers used it as a specific antigen to specifically culture an immune cell "CAR-T" that can attack myeloma cells. After transplanting it into experimental mice, the researchers found that this immune cell does not harm normal cells, only specifically kills myeloma cells, and has a good anti-cancer effect. The researchers believe that this suggests that this method is expected to become a new immunotherapy for the treatment of myeloma, they will begin clinical trials in 2019 to confirm the efficacy and safety. The results of this research have been published in the British journal Nature Medicine. Previously, research teams have tried to develop immunotherapy for multiple myeloma. Researchers at the University of Pennsylvania in 2015 reported an immunotherapy based on the transformation of patients' autoimmune cells to track and kill cancerous B cells, thereby treating multiple myeloma. Source: Xinhua News Agency Frozen Octopus Frozen octopus ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com